Immunocore Holdings (IMCR) EBITDA Margin (2021 - 2026)

Immunocore Holdings has reported EBITDA Margin for 6 years, with the latest figure at 6.82% in Q1 2026.

• Quarterly EBITDA Margin rose 1068.0% year-over-year to 6.82% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 8.35% (up 592.0% YoY) and the FY2025 annual result came in at 11.34%, up 1138.0% from the prior year.
• EBITDA Margin grew to 6.82% in Q1 2026 per IMCR's latest filing, from 18.85% in the prior quarter.
• Over five years, EBITDA Margin peaked at 14.98% in Q3 2022 and troughed at 51.43% in Q2 2022.
• A 5-year average of 19.97% and a median of 21.53% in 2023 frame the typical range for EBITDA Margin.
• The sharpest annual moves came in 2022 and 2023: EBITDA Margin soared 53743 bps in 2022, then slumped 3679 bps in 2023.
• Over 5 years, EBITDA Margin stood at 46.45% in 2022, then soared by 48 bps to 24.3% in 2023, then advanced by 5 bps to 23.14% in 2024, then climbed by 19 bps to 18.85% in 2025, then jumped by 136 bps to 6.82% in 2026.
• According to Business Quant data, EBITDA Margin over the past three periods registered 6.82%, 18.85%, and 6.92% for Q1 2026, Q4 2025, and Q3 2025 respectively.